Wan Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wan Wang has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Bin Wang
Pharmacology College, Xuzhou Medical University, Xuzhou 221004, China; Department of Laboratory Medicine, The Affiliated Hospital of Xuzhou Medical University, No.99 Huaihai West Road, Xuzhou, 221000, China
2 shared publications - Lin-Yan Huang
School of Medical Technology, Xuzhou Key Laboratory of Laboratory Diagnostics, Xuzhou Medical University, Tongshan Road 209, Xuzhou 221004, China
2 shared publications Linyan Huang
2 shared publicationsSuhua Qi
2 shared publications- Suhua Qi
School of Medical Technology, Xuzhou Key Laboratory of Laboratory Diagnostics, Xuzhou Medical University, Xuzhou, People’s Republic of China
2 shared publications - Yan-Ling Wang
Department of Laboratory Medicine, Affiliated Municipal First People’s Hospital of Xuzhou Medical University, Xuzhou, People’s Republic of China
2 shared publications
Latest Publications
- Open Access
- 8 October 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1666589
Extracellular vesicles in cardiovascular diseases: pathogenic mediators, diagnostic tools, and therapeutic vectors
Cardiovascular diseases (CVDs), the leading global cause of mortality, underscore an urgent need for innovative diagnostic and therapeutic strategies. Extracellular vesicles (EVs)—lipid-bilayer nanoparticles transporting bioactive cargo (microRNAs, proteins, lipids)—are critical mediators of intercellular communication in CVD pathogenesis. They exhibit functional duality: propagating pathology (inflammation, fibrosis, thrombosis) while facilitating tissue repair. This review synthesizes EV biogenesis mechanisms, isolation methodologies, source-specific functions, and multifaceted roles in atherosclerosis, myocardial infarction, heart failure, and stroke. We further evaluate EV-based diagnostic biomarkers, engineered therapeutic applications, clinical translation challenges, and future directions.
- 8 October 2025
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1666589
Open AccessExtracellular vesicles in cardiovascular diseases: pathogenic mediators, diagnostic tools, and therapeutic vectors
Cardiovascular diseases (CVDs), the leading global cause of mortality, underscore an urgent need for innovative diagnostic and therapeutic strategies. Extracellular vesicles (EVs)—lipid-bilayer nanoparticles transporting bioactive cargo (microRNAs, proteins, lipids)—are critical mediators of intercellular communication in CVD pathogenesis. They exhibit functional duality: propagating pathology (inflammation, fibrosis, thrombosis) while facilitating tissue repair. This review synthesizes EV biogenesis mechanisms, isolation methodologies, source-specific functions, and multifaceted roles in atherosclerosis, myocardial infarction, heart failure, and stroke. We further evaluate EV-based diagnostic biomarkers, engineered therapeutic applications, clinical translation challenges, and future directions.
- 2 September 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 784, 152579
Blockade of TGF-β1/Smad3 signaling pathway by Bovine Milk-derived extracellular vesicles ameliorates skin fibrosis in systemic sclerosis mice
- 2 September 2025
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 784, 152579
Blockade of TGF-β1/Smad3 signaling pathway by Bovine Milk-derived extracellular vesicles ameliorates skin fibrosis in systemic sclerosis mice
- 22 July 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-12
Disintegration of Cav-1/β-catenin complex attenuates neuronal death after ischemia–reperfusion injury by promoting β-catenin nuclear translocation
Background The roles of Caveolin-1 (Cav-1) and the Wnt/β-catenin signaling pathways in cerebral ischemia–reperfusion (I/R) injury are well established. The translocation of β-catenin into the nucleus is critical for regulating neuronal apoptosis, repair, and neurogenesis within the ischemic brain. It has been reported that the scaffold domain of Caveolin-1 (Cav-1) (residues 95–98) interacts with β-catenin (residues 330–337). However, the specific contribution of the Cav-1/β-catenin complex to I/R injury remains unknown. Methods and results To investigate the mechanism underlying the involvement of the Cav-1/β-catenin complex in the subcellular translocation of β-catenin and its subsequent effects on cerebral I/R injury, we treated ischemic brains with ASON (Cav-1 antisense oligodeoxynucleotides) or FTVT (a competitive peptide antagonist of the Cav-1 and β-catenin interaction). Our study demonstrated that the binding of Cav-1 to β-catenin following I/R injury prevented the nuclear accumulation of β-catenin. Treatment with ASON or FTVT after I/R injury significantly increased the levels of nuclear β-catenin. Furthermore, ASON reduced the phosphorylation of β-catenin at Ser33, Ser37, and Thr41, which contributes to its proteasomal degradation, while FTVT increased phosphorylation at Tyr333, which is associated with its nuclear translocation. Conclusions The above results indicate that the formation of the Cav-1/β-catenin complex anchors β-catenin in the cytoplasm following I/R injury. Additionally, both ASON and FTVT treatments attenuated neuronal death in ischemic brains. Our study suggests that targeting the interaction between Cav-1 and β-catenin serve as a novel therapeutic strategy to protect against neuronal damage during cerebral injury.
- 22 July 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-12
Disintegration of Cav-1/β-catenin complex attenuates neuronal death after ischemia–reperfusion injury by promoting β-catenin nuclear translocation
Background The roles of Caveolin-1 (Cav-1) and the Wnt/β-catenin signaling pathways in cerebral ischemia–reperfusion (I/R) injury are well established. The translocation of β-catenin into the nucleus is critical for regulating neuronal apoptosis, repair, and neurogenesis within the ischemic brain. It has been reported that the scaffold domain of Caveolin-1 (Cav-1) (residues 95–98) interacts with β-catenin (residues 330–337). However, the specific contribution of the Cav-1/β-catenin complex to I/R injury remains unknown. Methods and results To investigate the mechanism underlying the involvement of the Cav-1/β-catenin complex in the subcellular translocation of β-catenin and its subsequent effects on cerebral I/R injury, we treated ischemic brains with ASON (Cav-1 antisense oligodeoxynucleotides) or FTVT (a competitive peptide antagonist of the Cav-1 and β-catenin interaction). Our study demonstrated that the binding of Cav-1 to β-catenin following I/R injury prevented the nuclear accumulation of β-catenin. Treatment with ASON or FTVT after I/R injury significantly increased the levels of nuclear β-catenin. Furthermore, ASON reduced the phosphorylation of β-catenin at Ser33, Ser37, and Thr41, which contributes to its proteasomal degradation, while FTVT increased phosphorylation at Tyr333, which is associated with its nuclear translocation. Conclusions The above results indicate that the formation of the Cav-1/β-catenin complex anchors β-catenin in the cytoplasm following I/R injury. Additionally, both ASON and FTVT treatments attenuated neuronal death in ischemic brains. Our study suggests that targeting the interaction between Cav-1 and β-catenin serve as a novel therapeutic strategy to protect against neuronal damage during cerebral injury.
- Open Access
- 22 February 2024
- Published by Elsevier in Journal of Functional Foods
- Vol. 114
Exosome-like nanovesicles derived from Momordica charantia ameliorate delayed t-PA thrombolysis-induced hemorrhagic transformation by inhibiting the ONOO−/HMGB1/MMP-9 pathway
- 22 February 2024
- Published by Elsevier in Journal of Functional Foods
- Vol. 114
Open AccessExosome-like nanovesicles derived from Momordica charantia ameliorate delayed t-PA thrombolysis-induced hemorrhagic transformation by inhibiting the ONOO−/HMGB1/MMP-9 pathway
- Open Access
- 1 January 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 18 (5) , 1040-1045
Ischemic accumulation of succinate induces Cdc42 succinylation and inhibits neural stem cell proliferation after cerebral ischemia/reperfusion
JOURNAL/nrgr/04.03/01300535-202305000-00020/inline-graphic1/v/2022-10-11T005158Z/r/image-tiff
- 1 January 2023
- Published by Medknow in Neural Regeneration Research
- Vol. 18 (5) , 1040-1045
Open AccessIschemic accumulation of succinate induces Cdc42 succinylation and inhibits neural stem cell proliferation after cerebral ischemia/reperfusion
JOURNAL/nrgr/04.03/01300535-202305000-00020/inline-graphic1/v/2022-10-11T005158Z/r/image-tiff
- Open Access
- 7 August 2020
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (8)
KAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1
KRAB domain-associated protein 1 (KAP1) is highly expressed in atherosclerotic plaques. Here, we studied the role of KAP1 in atherosclerosis development using a cell model of endothelial dysfunction induced by oxidative low-density lipoprotein (OxLDL). The phosphorylation and protein levels of KAP1 were similar between OxLDL-treated and non-treated endothelial cells (ECs). KAP1 depletion significantly inhibited the production of OxLDL-enhanced reactive oxygen species and the expression of adhesion molecules in ECs. Treatment with OxLDL promoted the proliferation and migration of ECs, which was also confirmed by the elevated levels of the proliferative markers c-Myc and PCNA, as well as the migratory marker MMP-9. However, these effects were also abrogated by KAP1 depletion. Moreover, the depletion of KAP1 in OxLDL-treated ECs resulted in decreases in the LOX-1 level and increases in eNOS expression. Generally, the data suggest that strategies targeting KAP1 depletion might be particularly useful for the prevention or treatment of atherosclerosis.
- 7 August 2020
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 40 (8)
Open AccessKAP1 silencing relieves OxLDL-induced vascular endothelial dysfunction by down-regulating LOX-1
KRAB domain-associated protein 1 (KAP1) is highly expressed in atherosclerotic plaques. Here, we studied the role of KAP1 in atherosclerosis development using a cell model of endothelial dysfunction induced by oxidative low-density lipoprotein (OxLDL). The phosphorylation and protein levels of KAP1 were similar between OxLDL-treated and non-treated endothelial cells (ECs). KAP1 depletion significantly inhibited the production of OxLDL-enhanced reactive oxygen species and the expression of adhesion molecules in ECs. Treatment with OxLDL promoted the proliferation and migration of ECs, which was also confirmed by the elevated levels of the proliferative markers c-Myc and PCNA, as well as the migratory marker MMP-9. However, these effects were also abrogated by KAP1 depletion. Moreover, the depletion of KAP1 in OxLDL-treated ECs resulted in decreases in the LOX-1 level and increases in eNOS expression. Generally, the data suggest that strategies targeting KAP1 depletion might be particularly useful for the prevention or treatment of atherosclerosis.